

8. REFERENCES

1. Herfindal E, Helms R. Breast Cancer. In: Jones SF, Burris HA, editors. Textbook of Therapeutics Drug and Disease Management, 8th Ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 2358-77.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. *A Cancer Journal for Clinicians* 2017;67(1):7-30.
3. Satyanarayana L, Asthana S. Life time risk for development of ten major cancers in India and its trends over the years 1982 to 2000. *Indian Journal of Medical Sciences* 2008;62(2):35-44.
4. Dsouza ND, Murthy N, Aras R. Projection of cancer incident cases for India-till 2026. *Asian Pacific Journal of Cancer Prevention* 2013;14(7):4379-86.
5. Uma Devi K. Current status of gynecological cancer care in India. *Journal of Gynecologic Oncology* 2009;20(2):77-80.
6. Bari SB, Adhikari S, Surana SJ. Tyrosine Kinase Receptor Inhibitors: A New Target for Anticancer Drug Development. *Journal of PharmaSciTech* 2012;1(2), 36-45.
7. Kumar P, Bolshette NB, Jamdade VS, Mundhe NA, Thakur KK, Saikia KK, et al. Breast cancer status in India: an overview. *Biomedicine & Preventive Nutrition* 2013;3(2):177-83.
8. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? *Journal of Clinical Oncology* 2005;23(29):7350-60.
9. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network* 2018;16(3):310-20.
10. Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, et al. Breast cancer, version 3.2013. *Journal of the National Comprehensive Cancer Network* 2013;11(7):753-61.
11. Gärtner R, Jensen M-B, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. *Jama* 2009;302(18):1985-92.
12. Stearns V, Gelmann EP. Does tamoxifen cause cancer in humans? *Journal of Clinical Oncology* 1998;16(2):779-92.
13. Harris JR, Lippman ME, Osborne CK, Morrow M. Diseases of the Breast. In: Mancino AT. *Diseases of the Breast*, 2nd Ed. Philadelphia: Lippincott Williams & Wilkins; 2001.
14. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. *Journal of the National Cancer Institute* 2011;103(17):1299-309.

15. National Cancer Institute. Radiation therapy and you: support for people with cancer. 2016.
16. Rockwell S, Liu Y, Higgins SA. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. *Breast Cancer Research and Treatment* 2005;90(3):233-9.
17. Hartwell JL. Plants used against cancer. A survey. *Lloydia* 1970;33(1):97-194.
18. Graham J, Quinn M, Fabricant D, Farnsworth N. Plants used against cancer—an extension of the work of Jonathan Hartwell. *Journal of Ethnopharmacology* 2000;73(3):347-77.
19. Cragg GM, Kingston DG, Newman DJ. *Anticancer agents from natural products*, 2nd Ed. Boca Raton: CRC press-Taylor and Francis Group; 2011.
20. Nirmala MJ, Samundeeswari A, Sankar PD. Natural plant resources in anti-cancer therapy-A review. *Research in Plant Biology* 2011;1(3):1-13.
21. Wagner H. Synergy research: approaching a new generation of phytopharmaceuticals. *Fitoterapia* 2011;82(1):34-7.
22. Mangathayaru K. *Pharmacognosy: An Indian perspective*, 1st Ed. Chennai: Pearson Education India; 2013.
23. Rasoanaivo P, Wright CW, Willcox ML, Gilbert B. Whole plant extracts versus single compounds for the treatment of malaria: synergy and positive interactions. *Malaria Journal* 2011;10(Suppl 1):S4:1-12.
24. Gallily R, Yekhtin Z, Hanus LO. Overcoming the bell-shaped dose-response of cannabidiol by using Cannabis extract enriched in cannabidiol. *Pharmacology & Pharmacy* 2015;6(2):75-85.
25. Solowey E, Lichtenstein M, Sallon S, Paavilainen H, Solowey E, Lorberboum-Galski H. Evaluating medicinal plants for anticancer activity. *The Scientific World Journal* 2014;2014:1-13.
26. Arora N, Koul A. A ‘complex solution’ to a ‘complex’ problem: tackling the complexity of cancer with botanicals. *European Journal of Cancer Prevention* 2014;23(6):568-78.
27. Gunakkunru A, Padmanaban K, Thirumal P, Pritila J, Parimala G, Vengatesan N, et al. Anti-diarrhoeal activity of *Butea monosperma* in experimental animals. *Journal of Ethnopharmacology* 2005;98(3):241-4.
28. Sehwat A, Sultana S. Chemoprevention by *Butea monosperma* of hepatic carcinogenesis and oxidative damage in male wistar rats. *Asian Pacific Journal of Cancer Prevention* 2006;7(1):140-8.
29. Sehwat A, Kumar V. Butein imparts free radical scavenging, anti-oxidative and proapoptotic properties in the flower extracts of *Butea monosperma*. *Biocell* 2012;36(2):63-71.

30. Geeta R, Prakash R, Navgeet S, Neeru V, Sumit J. *Butea monosperma* (Lam.) Kuntze: A Review. International Research Journal of Pharmacy 2011;2(7):98-108.
31. Sharma AK, Deshwal N. An overview: on phytochemical and pharmacological studies of *Butea monosperma*. International Journal of PharmTech Research 2011;3(2):864-87.
32. Kamboj V, Dhawan B. Research on plants for fertility regulation in India. Journal of Ethnopharmacology 1982;6(2):191-226.
33. Bandara B, Kumar NS, Samaranyake K. An antifungal constituent from the stem bark of *Butea monosperma*. Journal of Ethnopharmacology 1989;25(1):73-5.
34. Mazumder P, Das M, Das S. *Butea monosperma* (Lam) Kuntze-A comprehensive review. International Journal of Pharmaceutical Sciences and Nanotechnology 2011;4(2):1390-3.
35. Wang Y, Chan FL, Chen S, Leung LK. The plant polyphenol butein inhibits testosterone-induced proliferation in breast cancer cells expressing aromatase. Life sciences 2005;77(1):39-51.
36. Stajčić S, Četković G, Čanadanović-Brunet J, Djilas S, Mandić A, Četojević-Simin D. Tomato waste: Carotenoids content, antioxidant and cell growth activities. Food chemistry 2015;172:225-32.
37. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. Journal of the National Cancer Institute 1999;91(4):317-31.
38. Giovannucci E. A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. Experimental Biology and Medicine 2002;227(10):852-9.
39. Palozza P, Simone RE, Catalano A, Mele MC. Tomato lycopene and lung cancer prevention: from experimental to human studies. Cancers 2011;3(2):2333-57.
40. Yang T, Yang X, Wang X, Wang Y, Song Z. The role of tomato products and lycopene in the prevention of gastric cancer: A meta-analysis of epidemiologic studies. Medical hypotheses 2013;80(4):383-8.
41. Bhowmik D, Kumar KS, Paswan S, Srivastava S. Tomato-a natural medicine and its health benefits. Journal of Pharmacognosy and Phytochemistry 2012;1(1):33-43.
42. Navarrete S, Alarcón M, Palomo I. Aqueous extract of tomato (*Solanum lycopersicum* L.) and ferulic acid reduce the expression of TNF- α and IL-1 β in LPS-activated macrophages. Molecules 2015;20(8):15319-29.
43. Jamshidzadeh A, Baghban M, Azarpira N, Bardbori AM, Niknahad H. Effects of tomato extract on oxidative stress induced toxicity in different organs of rats. Food and Chemical Toxicology 2008;46(12):3612-5.
44. Karimi G, Ramezani M, Abdi A. Protective effects of lycopene and tomato extract against doxorubicin-induced cardiotoxicity. Phytotherapy Research 2005;19(10):912-4.

45. Wang Y, Ausman LM, Greenberg AS, Russell RM, Wang XD. Dietary lycopene and tomato extract supplementations inhibit nonalcoholic steatohepatitis-promoted hepatocarcinogenesis in rats. *International Journal of Cancer* 2010;126(8):1788-96.
46. Yang CM, Yen YT, Huang CS, Hu ML. Growth inhibitory efficacy of lycopene and β -carotene against androgen-independent prostate tumor cells xenografted in nude mice. *Molecular nutrition & food research* 2011;55(4):606-12.
47. Balunas MJ, Su B, Brueggemeier RW, Kinghorn AD. Natural products as aromatase inhibitors. *Anti-cancer Agents in Medicinal Chemistry* 2008;8(6):646-82.
48. Hirsch K, Atzmon A, Danilenko M, Levy J, Sharoni Y. Lycopene and other carotenoids inhibit estrogenic activity of 17β -estradiol and genistein in cancer cells. *Breast Cancer Research and Treatment* 2007;104(2):221.
49. Maggio M, de Vita F, Lauretani F, Bandinelli S, Semba RD, Bartali B, et al. Relationship between carotenoids, retinol, and estradiol levels in older women. *Nutrients* 2015;7(8):6506-19.
50. Duraipandiyar V, Baskar AA, Ignacimuthu S, Muthukumar C, Al-Harbi N. Anticancer activity of Rhein isolated from *Cassia fistula* L. flower. *Asian Pacific Journal of Tropical Disease* 2012;2(1):S517-S523.
51. Danish M, Singh P, Mishra G, Srivastava S, Jha K, Khosa R. *Cassia fistula* Linn.(Amulthus)—an important medicinal plant: A review of its traditional uses, phytochemistry and pharmacological properties. *Journal of Natural Product and Plant Resources* 2011;1(1):101-18.
52. Vasudevan K, Manoharan S, Alias LM, Balakrishnan S, Vellaichamy L, Gitanjali M. Evaluation of Chemopreventive Efficacy of *Cassia fistula* in 7, 12 Dimethyl Benz (A) Anthracene (DMBA) induced Oral Carcinogenesis. *International Journal of Chemical Sciences* 2008;1(1):101-118.
53. Yadav R, Jain G. Effect of petroleum ether extract of *Cassia fistula* seeds on uterine histoarchitecture of ovariectomized female rats. *Indian Journal of Fundamental and Applied Life Sciences* 2013;3(1):167-174.
54. Saleem M. Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. *Cancer letters* 2009;285(2):109-15.
55. Standring S. Chest Wall and Breast. In: Gatzoulis M., Johnson M., editors *Gray's anatomy e-book: the anatomical basis of clinical practice* 40th Ed. Elsevier Health Sciences-Churchill Livingstone; 2015. p. 163-173.
56. Hassiotou F, Geddes D. Anatomy of the human mammary gland: Current status of knowledge. *Clinical Anatomy* 2013;26(1):29-48.
57. Love SM. Dr. Susan Love's breast book: Da Capo Lifelong Books. *Journal of National Cancer Institute*, 2015; 85: 892-897.

58. Fata JE, Werb Z, Bissell MJ. Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes. *Breast Cancer Research* 2003;6(1):1-11.
59. Neville MC, McFadden TB, Forsyth I. Hormonal regulation of mammary differentiation and milk secretion. *Journal of Mammary Gland Biology And Neoplasia* 2002;7(1):49-66.
60. Inman JL, Robertson C, Mott JD, Bissell MJ. Mammary gland development: cell fate specification, stem cells and the microenvironment. *Development* 2015;142(6):1028-42.
61. Lyons WR. Hormonal synergism in mammary growth. *Proceedings of Royal Society of London, Series B. Biological Sciences*; 1958;149(936): 302-25.
62. Chuong C-M, Bhat R, Widelitz RB, Bissell MJ. SnapShot: branching morphogenesis. *Cell* 2014;158(5):156-58.
63. Hennighausen L, Robinson GW. Information networks in the mammary gland. *Nature Reviews. Molecular Cell Biology* 2005;6(9):715-25.
64. Deventer PV, Graewe FR. The blood supply of the breast revisited. *Plastic and Reconstructive Surgery* 2016;137(5):1388-97.
65. Cunningham L. The anatomy of the arteries and veins of the breast. *Journal of Surgical Oncology* 1977;9(1):71-85.
66. Claus EB, Chu P, Howe CL, Davison TL, Stern DF, Carter D, et al. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. *Experimental and Molecular Pathology* 2001;70(3):303-16.
67. Carolin KA, Tekyi-Mensah S, Pass HA. Lobular carcinoma in situ and invasive cancer: the contralateral breast controversy. *The Breast Journal* 2002;8(5):263-8.
68. Hanby A, Hughes T. In situ and invasive lobular neoplasia of the breast. *Histopathology* 2008;52(1):58-66.
69. Dixon JM. Breast Cancer: Epidemiology, Risk Factors and Genetics. In: Sestak I, Cuzick J and Evans G, editors. *ABC of Breast Diseases*, 4th Ed. John Wiley & Sons; 2012. p. 41-46.
70. Klinge CM. Estrogen receptor interaction with co-activators and co-repressors. *Steroids* 2000;65(5):227-51.
71. Anderson E. Progesterone receptors-animal models and cell signaling in breast cancer: The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. *Breast Cancer Research* 2002;4(5):197-201.
72. Bocchinfuso WP, Lindzey JK, Hewitt SC, Clark JA, Myers PH, Cooper R, et al. Induction of mammary gland development in estrogen receptor- α knockout mice. *Endocrinology* 2000;141(8):2982-94.

73. Förster C, Mäkela S, Wärrä A, Kietz S, Becker D, Hultenby K, et al. Involvement of estrogen receptor β in terminal differentiation of mammary gland epithelium. *Proceedings of the National Academy of Sciences* 2002;99(24):15578-83.
74. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. *Endocrine Reviews* 1997;18(4):502-19.
75. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. *Breast Cancer Research* 2007;9(1).
76. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. *Journal of clinical Oncology* 1999;17(9):2639-48.
77. Slamon DJ, Clark GM. Amplification of c-erbB-2 and Aggressive Human Breast Tumors?. *Science* 1988;240(4860):1795-8.
78. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proceedings of the National Academy of Sciences* 2003;100(14):8418-23.
79. Perou CM, Sørlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. *Nature* 2000;406(6797):747.
80. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. *Nature Medicine* 2008;14(5):518.
81. Ma X-J, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, et al. Gene expression profiles of human breast cancer progression. *Proceedings of the National Academy of Sciences* 2003;100(10):5974-9.
82. Gruvberger S, Ringnér M, Chen Y, Panavally S, Saal LH, Borg Å, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. *Cancer Research* 2001;61(16):5979-84.
83. Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E, et al. Impact of DNA amplification on gene expression patterns in breast cancer. *Cancer Research* 2002;62(21):6240-5.
84. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proceedings of the National Academy of Sciences* 2001;98(19):10869-74.
85. Hu Z, Fan C, Oh DS, Marron J, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. *BMC genomics* 2006;7(1):96-107.

86. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. *Clinical Cancer Research* 2005;11(16):5678-85.
87. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. *Journal of Clinical Oncology* 2010;28(10):1684-91.
88. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. *Journal of the National Cancer Institute* 2014;106(5):1-8.
89. Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, et al. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node–negative disease: results from International Breast Cancer Study Group Trials VIII and IX. *Journal of Clinical Oncology* 2013;31(25):3083-90.
90. McGuire A, Lowery AJ, Kell MR, Kerin MJ, Sweeney KJ. Locoregional recurrence following breast cancer surgery in the trastuzumab era: A systematic review by subtype. *Annals of Surgical Oncology* 2017;24(11):3124-32.
91. Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong Y-N, Edge SB, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. *Journal of Clinical Oncology* 2016;34(27):3308-14.
92. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression–based predictors for breast cancer. *New England Journal of Medicine* 2006;355(6):560-9.
93. Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. *Journal of the National Cancer Institute* 2015;107(6):1-25.
94. Sineshaw HM, Gaudet M, Ward EM, Flanders WD, Desantis C, Lin CC, et al. Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010–2011). *Breast Cancer Research and Treatment* 2014;145(3):753-63.
95. Carey LA, Cheang MCU, Perou CM. Genomics, prognosis, and therapeutic interventions. In: Harris JR, Lippman ME, Morrow M, Osborne CK editors. *Diseases of the Breast*, 5th Ed. USA: Lippincott Williams and Wilkins; 2014.
96. Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. *Journal of Clinical Oncology* 2009;27(28):4701-8.

97. Ries L, Melbert D, Krapcho M, Stinchcomb D, Howlander N, Horner M, et al. SEER Cancer Statistics Review, 1975–2014; National Cancer Institute. Available at: https://seer.cancer.gov/csr/1975_2005/
98. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *A Cancer Journal for Clinicians* 2018;68(1):7-30.
99. Calle EE, Heath CW, McMahon HL, Coates RJ, Liff JM, Franceschi S, et al.. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. *The Lancet* 2001;358(9291):1389-99.
100. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. *International Journal of Cancer* 1997;71(5):800-9.
101. Kharazmi E, Chen T, Narod S, Sundquist K, Hemminki K. Effect of multiplicity, laterality, and age at onset of breast cancer on familial risk of breast cancer: a nationwide prospective cohort study. *Breast Cancer Research and Treatment* 2014;144(1):185-92.
102. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. *International Journal of Radiation Oncology, Biology, Physics* 2003;56(4):1038-45.
103. Ibrahim EM, Abouelkhair KM, Kazkaz GA, Elmasri OA, Al-Foheidi M. Risk of second breast cancer in female Hodgkin's lymphoma survivors: a meta-analysis. *BMC cancer* 2012;12(1):197-226.
104. Willet W, Rockhill B, Hankinson S, Hunter D, Colditz G. Genetic testing and management of patients with hereditary breast cancer. In: Isaacs C, Peshkin B, Schwartz M. *Diseases of the Breast* 4th ed Philadelphia: Lippincott Williams & Wilkins, 2010:224-47.
105. Ewertz M, Duffy SW, Adami HO, Kvåle G, Lund E, Meirik O, et al. Age at first birth, parity and risk of breast cancer: A meta-analysis of 8 studies from the nordic countries. *International Journal of Cancer* 1990;46(4):597-603.
106. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. *American Journal of Epidemiology* 1994;139(8):819-35.
107. Willet W, Rockhill B, Hankinson S, Hunter D, Colditz G. Nongenetic factors in the causation of breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. *Diseases of the Breast*, 4th Ed. Philadelphia: Lippincott Williams & Wilkins, 2004:221-76.
108. Ritte R, Tikk K, Lukanova A, Tjønneland A, Olsen A, Overvad K, et al. Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study. *BMC Cancer* 2013;13(1):584-96.

109. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer. *New England Journal of Medicine* 1992;327(5):319-28.
110. Beral V, Bull D, Doll R, Peto R, Reeves G, van den Brandt P, et al. Collaborative Group on Hormonal Factors in Breast cancer: Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83000 women with breast cancer from 16 countries. *The Lancet* 2004;363(9414):1007-16.
111. Calle EE, Heath CW, McMahon HL, Coates RJ, Liff JM, Franceschi S, et al. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. *The Lancet* 1996;347(9017):1713-27.
112. Hankinson SE, Colditz GA, Manson JE, Willett WC, Hunter DJ, Stampfer MJ, et al. A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States). *Cancer Causes & Control* 1997;8(1):65-72.
113. Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. *Cancer Epidemiology and Prevention Biomarkers* 2013;22(11):1931-43.
114. Gapstur S, Morrow M, Sellers T. Hormonal Replacement Therapy and Risk of Breast Cancer with a favorable histology: results of the Iowa Women's Health Study. *Jama* 1999;281(22):2091-7.
115. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. *Jama* 2000;283(4):485-91.
116. Calle, EE, Heath CW Jr, Miracle-McMahon HL, Coates RJ, Liff JM, Franceschi S, et al. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. *The Lancet* 1997;350(9084):1047-59.
117. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. *New England Journal of Medicine* 1995;332(24):1589-93.
118. Fahlén M, Fornander T, Johansson H, Johansson U, Rutqvist L-E, Wilking N, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. *European Journal of Cancer* 2013;49(1):52-9.
119. Holmberg L, Iversen O-E, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. *Journal of the National Cancer Institute* 2008;100(7):475-82.
120. Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW Jr, et al. Alcohol, tobacco and breast cancer—collaborative reanalysis of individual data from 53

- epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. *British Journal of Cancer* 2002;87(11):1234-1245.
121. Stampfer MJ, Hennekens CH, Speizer M. Dual effects of weight and weight gain on breast cancer risk. *Jama* 1997;278:1407-11.
122. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. *BMJ* 2007;335(7630):1134-45.
123. Ellisen LW, Haber DA. Hereditary breast cancer. *Annual Review of Medicine* 1998;49(1):425-36.
124. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. *Journal of Clinical Oncology* 2007;25(11):1329-33.
125. Hill A, Doyle J, McDermott E, O'higgins N. Hereditary breast cancer. *British Journal of Surgery* 1997;84(10):1334-9.
126. Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA. BRCA1 mutations in a population-based sample of young women with breast cancer. *New England Journal of Medicine* 1996;334(3):137-42.
127. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, et al. BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. *Jama* 1996;275(24):1885-92.
128. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the US Preventive Services Task Force. *Annals of Internal Medicine* 2002;137(5):347-60.
129. Institute of Medicine (US) and National Research Council (US) Committee on New Approaches to Early Detection and Diagnosis of Breast Cancer. *Saving women's lives: strategies for improving breast cancer detection and diagnosis*. Washington: National Academies Press; 2005.
130. Calonge N, Petitti DB, DeWitt TG, Dietrich AJ, Gregory KD, Grossman D, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2009;151(10):716-26.
131. Eddy DM. Screening for breast cancer. *Annals of Internal Medicine* 1989;111(5):389-99.
132. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten-to fourteen-year effect of screening on breast cancer mortality. *Journal of the National Cancer Institute* 1982;69(2):349-55.
133. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. *Jama* 2005;293(10):1245-56.
134. Moore FD. Breast self-examination. *The New England Journal of Medicine* 1978;299(6):304-305.
135. Baines CJ. Breast self-examination. *Cancer* 1989;64(S2):2661-3.

136. Greenwald P, Nasca PC, Lawrence CE, Horton J, McGarrah RP, Gabriele T, et al. Estimated effect of breast self-examination and routine physician examinations on breast-cancer mortality. *New England Journal of Medicine* 1978;299(6):271-3.
137. Koibuchi Y, Iino Y, Takei H, Maemura M, Horiguchi J, Yokoe T, et al. The effect of mass screening by physical examination combined with regular breast self-examination on clinical stage and course of Japanese women with breast cancer. *Oncology Reports* 1998;5(1):151-6.
138. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *A Cancer Journal for Clinicians* 2007;57(2):75-89.
139. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the US Preventive Services Task Force. *Annals of Internal Medicine* 2009;151(10):727-37.
140. Dowlatshahi K, Yaremko M, Kluskens L, Jokich P. Nonpalpable breast lesions: findings of stereotaxic needle-core biopsy and fine-needle aspiration cytology. *Radiology* 1991;181(3):745-50.
141. Dennison G, Anand R, Makar S, Pain J. A prospective study of the use of fine-needle aspiration cytology and core biopsy in the diagnosis of breast cancer. *The Breast Journal* 2003;9(6):491-3.
142. Elvecrog E, Lechner M, Nelson M. Nonpalpable breast lesions: correlation of stereotaxic large-core needle biopsy and surgical biopsy results. *Radiology* 1993;188(2):453-5.
143. Kaufmann M, Morrow M, Minckwitz G, Harris JR. Locoregional treatment of primary breast cancer. *Cancer* 2010;116(5):1184-91.
144. Vilholm OJ, Cold S, Rasmussen La, Sindrup SH. The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer. *British Journal of Cancer* 2008;99(4):604-610.
145. Camarillo CL. The importance of cancer cell lines as *in-vitro* models in cancer methylome analysis and anticancer drugs testing. In: Ferreira D, Adegá F, Chaves R., editors. *Oncogenomics and Cancer Proteomics-Novel Approaches in Biomarkers Discovery and Therapeutic Targets in Cancer*, 1st Ed. InTechOpen; 2013. p.139-166
146. Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-derived cell lines as molecular models of cancer pharmacogenomics. *Molecular Cancer Research* 2016;14(1):3-13.
147. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. *Nature Reviews. Cancer* 2007;7(9):659-72.
148. Van Staveren W, Solís DW, Hebrant A, Detours V, Dumont JE, Maenhaut C. Human cancer cell lines: Experimental models for cancer cells in situ? For cancer stem cells? *Biochimica et Biophysica Acta-Reviews on Cancer* 2009;1795(2):92-103.

149. Macejova D, Brtko J. Chemically induced carcinogenesis: a comparison of 1-methyl-1-nitrosourea, 7, 12-dimethylbenzanthracene, diethylnitroso-amine and azoxymethan models. *Endocrine Regulations* 2001;35(1):53-60.
150. Thompson HJ, Meeker LD. Induction of mammary gland carcinomas by the subcutaneous injection of 1-methyl-1-nitrosourea. *Cancer Research* 1983;43(4):1628-9.
151. Tsubura A, Lai Y-C, Miki H, Sasaki T, Uehara N, Yuri T, et al. Animal models of N-methyl-N-nitrosourea-induced mammary cancer and retinal degeneration with special emphasis on therapeutic trials. *In vivo* 2011;25(1):11-22.
152. Löscher W, Mevissen M, Häussler B. Seasonal influence on 7, 12-dimethylbenz [a] anthracene-induced mammary carcinogenesis in Sprague-Dawley rats under controlled laboratory conditions. *Pharmacology & Toxicology* 1997;81(6):265-70.
153. Bentrem DJ, Jordan VC. Targeted antiestrogens for the prevention of breast cancer. *Oncology Research* 1999;11(9):401-7.
154. Ahlem CN, Frincke JM, White SK, Reading CL, Trauger RJ, Lakshmanaswamy R. 17 α -Ethinyl-5 α -androstane-3 α , 17 β -diol treatment of MNU-Induced mammary cancer in Rats. *International Journal of Breast Cancer* 2011;2011:1-9.
155. Sukumar S, McKenzie K, Chen Y. Animal models for breast cancer. *Mutation Research* 1995;333(1):37-44.
156. Parvathaneni M, Battu GR, Gray AI, Gummalla P. Investigation of anticancer potential of hypophyllanthin and phyllanthin against breast cancer by *in-vitro* and *in-vivo* methods. *Asian Pacific Journal of Tropical Disease* 2014;4:S71-S6.
157. Jagadeesan J, Langeswaran K, Gowthamkumar S, Balasubramanian MP. Diosgenin exhibits beneficial efficiency on human mammary carcinoma cell line MCF-7 and against N-nitroso-N-methylurea (NMU) induced experimental mammary carcinoma. *Biomedicine & Preventive Nutrition* 2013;3(4):381-8.
158. Parikh RR, Gildener-Leapman N, Narendran A, Lin H-Y, Lemanski N, Bennett JA, et al. Prevention of N-Methyl-N-Nitrosourea-Induced Breast Cancer by α -Fetoprotein (AFP)-Derived Peptide, a Peptide Derived from the Active Site of AFP. *Clinical Cancer Research* 2005;11(23):8512-20.
159. Thompson HJ, Adlakha H, Singh M. Effect of carcinogen dose and age at administration on induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. *Carcinogenesis* 1992;13(9):1535-9.
160. Thompson HJ, Adlakha H. Dose-responsive induction of mammary gland carcinomas by the intraperitoneal injection of 1-methyl-1-nitrosourea. *Cancer Research* 1991;51(13):3411-5.
161. Tsubura A, Uehara N, Matsuoka Y, Yoshizawa K, Yuri T. Estrogen and progesterone treatment mimicking pregnancy for protection from breast cancer. *In vivo* 2008;22(2):191-201.

162. Yang J, Yoshizawa K, Nandi S, Tsubura A. Protective effects of pregnancy and lactation against N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. *Carcinogenesis* 1999;20(4):623-8.
163. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. *Cancer Research* 2006;66(7):3351-4.
164. Murphy J. Pre-clinical murine models: Syngeneic models for immuno-oncology. *MOJ Immunology* 2015;2(4):52.
165. Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. *Disease Models & Mechanisms* 2008;1(2-3):78-82.
166. Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. *The American Journal of Pathology* 2007;170(3):793-804.
167. Day C-P, Merlino G, Van Dyke T. Preclinical mouse cancer models: a maze of opportunities and challenges. *Cell* 2015;163(1):39-53.
168. Egami K, Murohara T, Shimada T, Sasaki K-i, Shintani S, Sugaya T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. *The Journal of Clinical Investigation* 2003;112(1):67-75.
169. Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. *Nature Communications* 2013;4:2516-27.
170. Napoleone E, Cutrone A, Cugino D, Amore C, Di Santo A, Iacoviello L, et al. Inhibition of the renin-angiotensin system downregulates tissue factor and vascular endothelial growth factor in human breast carcinoma cells. *Thrombosis Research* 2012;129(6):736-42.
171. Okazaki M, Fushida S, Harada S, Tsukada T, Kinoshita J, Oyama K, et al. The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer. *Cancer Letters* 2014;355(1):46-53.
172. Du H, Liang Z, Zhang Y, Jie F, Li J, Fei Y, et al. Effects of angiotensin II type 2 receptor overexpression on the growth of hepatocellular carcinoma cells *in-vitro* and *in-vivo*. *PLOS one* 2013;8(12):e83754.
173. Passos-Silva DG, Brandan E, Santos RAS. Angiotensins as therapeutic targets beyond heart disease. *Trends in Pharmacological sciences* 2015;36(5):310-20.
174. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011;144(5):646-74.
175. Fleming TP, Matsui T, Molloy CJ, Robbins KC, Aaronson SA. Autocrine mechanism for v-sis transformation requires cell surface localization of internally activated growth factor receptors. *Proceedings of the National Academy of Sciences* 1989;86(20):8063-7.

176. Clark GJ, Der CJ. Aberrant function of the Ras signal transduction pathway in human breast cancer. *Breast Cancer Research and Treatment* 1995;35(1):133-44.
177. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. *Nature Reviews Cancer* 2011;11(8):558-72.
178. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. *Nature* 2012;490(7418):61-70.
179. Blagosklonny MV. Flavopiridol, an inhibitor of transcription: implications, problems and solutions. *Cell Cycle* 2004;3(12):1537-42.
180. Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. *Blood* 1998;92(10):3804-16.
181. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. *Blood* 2000;96(2):393-7.
182. Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zaccarola PF, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. *Clinical Cancer Research* 2001;7(6):1590-9.
183. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase–AKT pathway in human cancer. *Nature Reviews Cancer* 2002;2(7):489-501.
184. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and cancer. *Annual Review of Cell and Developmental Biology* 2001;17(1):615-75.
185. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. *Apoptosis* 2004;9(6):667-76.
186. Burris HA. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. *Cancer Chemotherapy and Pharmacology* 2013;71(4):829-42.
187. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. *Journal of Clinical Oncology* 2011;29(33):4452-61.
188. Razis E, Bobos M, Kotoula V, Eleftheraki A, Kalofonos H, Pavlakis K, et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. *Breast Cancer Research and Treatment* 2011;128(2):447-56.

189. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birlle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. *Journal of Clinical Oncology* 2011;30(3):282-90.
190. Ando Y, Inada-Inoue M, Mitsuma A, Yoshino T, Ohtsu A, Suenaga N, et al. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. *Cancer Science* 2014;105(3):347-53.
191. Maass N, Harbeck N, Mundhenke C, Lerchenmüller C, Barinoff J, Lück H-J, et al. Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. *Journal of Cancer Research and Clinical Oncology* 2013;139(12):2047-56.
192. Hosford SR, Miller TW. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. *Pharmacogenomics and Personalized Medicine* 2014;7:203-15.
193. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. *Journal of Clinical Oncology* 2008;26(25):4078-85.
194. Dunn SE, Hardman RA, Kari FW, Barrett JC. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. *Cancer Research* 1997;57(13):2687-93.
195. Haluska P, Shaw H, Batzel G, Molife L, Adjei A, Yap T, et al. Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors. *Journal of Clinical Oncology* 2007;25(18_suppl):3586.
196. Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death—proliferative and anti-apoptotic effects. *Breast Cancer Research and Treatment* 1999;56(1):1-10.
197. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. *Nature* 2005;434(7035):913-7.
198. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 2005;434(7035):917-21.
199. Murai J, Shar-yin NH, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. *Cancer Research* 2012;72(21):5588-99.
200. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. *The Lancet* 2010;376(9737):235-44.

201. Fan J, Yin W-J, Lu J-S, Wang L, Wu J, Wu F-Y, et al. ER α negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. *Journal of Cancer Research and Clinical Oncology* 2008;134(8):883-90.
202. Jang ER, Lim S-J, Lee ES, Jeong G, Kim T-Y, Bang Y-J, et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α -negative breast cancer cells to tamoxifen. *Oncogene* 2004;23(9):1724-36.
203. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. *Journal of Clinical Oncology* 2013;31(17):2128-35.
204. Munster P, Thurn K, Thomas S, Raha P, Lincecum M, Miller A, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. *British Journal of Cancer* 2011;104(12):1828-35.
205. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. *Biochimica et Biophysica Acta-Reviews on Cancer* 2002;1602(2):114-30.
206. Zhang XH-F, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. *Cancer Cell* 2009;16(1):67-78.
207. Elsberger B, Tan BA, Mitchell TJ, Brown SB, Mallon EA, Tovey SM, et al. Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR-and HER2-negative breast cancer patients? *The American Journal of Pathology* 2009;175(4):1389-97.
208. Morgan L, Gee J, Pumford S, Farrow L, Finlay P, Robertson J, et al. Elevated Src kinase activity attenuates Tamoxifen response *in-vitro* and is associated with poor prognosis clinically. *Cancer Biology & Therapy* 2009;8(16):1550-8.
209. Herold CI, Chadaram V, Peterson BL, Marcom PK, Hopkins J, Kimmick GG, et al. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. *Clinical Cancer Research* 2011;17(18):6061-70.
210. Fedele P, Calvani N, Marino A, Orlando L, Schiavone P, Quaranta A, et al. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going? *Critical Reviews in Oncology/Hematology* 2012;84(2):243-51.
211. Fornier M, Morris P, Abbruzzi A, D'andrea G, Gilewski T, Bromberg J, et al. A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. *Annals of Oncology* 2011;22(12):2575-81.

212. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine J-C, Teglund S, et al. Jak2 is essential for signaling through a variety of cytokine receptors. *Cell* 1998;93(3):385-95.
213. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. *Nature Reviews. Cancer* 2007;7(9):673-83.
214. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell* 2005;7(4):387-97.
215. Sansone P, Bromberg J. Targeting the interleukin-6/Jak/Stat pathway in human malignancies. *Journal of Clinical Oncology* 2012;30(9):1005-14.
216. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+ CD24–stem cell–like breast cancer cells in human tumors. *The Journal of Clinical Investigation* 2011;121(7):2723-35.
217. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. *Oncology* 2005;69(Suppl. 3):4-10.
218. Schneider WC. [99] Determination of nucleic acids in tissues by pentose analysis. *Methods in Enzymology* 1957;3:680-684.
219. Burton K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. *Biochemical Journal* 1956;62(2): 315–323.
220. Akanmu M, Iwalewa E, Elujoba A, Adelusola K. Toxicity potentials of *Cassia fistula* fruits as laxative with reference to Senna. *African Journal of Biomedical Research* 2004;7(1):23-26.
221. Khan W, Gupta S, Ahmad S. Toxicology of the aqueous extract from the flowers of *Butea monosperma* Lam. and its metabolomics in yeast cells. *Food and Chemical Toxicology* 2017;108(Pt B):486-97.
222. Sonkar N, Ganeshpurkar A, Yadav P, Dubey S, Bansal D, Dubey N. An experimental evaluation of nephroprotective potential of *Butea monosperma* extract in albino rats. *Indian Journal of Pharmacology* 2014;46(1):109-12.
223. Phachonpai W, Muchimapura S, Tong-Un T, Wattanathorn J, Thukhammee W, Thipkaew C, Sripanidkulchai B, Wannanon P. Acute toxicity study of tomato pomace extract in rodent. *Online Journal of Biological Sciences* 2013;13(1):28-34.
224. Samudrala PK, Augustine BB, Kasala ER, Bodduluru LN, Barua C, Lahkar M. Evaluation of antitumor activity and antioxidant status of *Alternanthera brasiliana* against Ehrlich ascites carcinoma in Swiss albino mice. *Pharmacognosy Research* 2015;7(1):66-73.

225. Salar RK, Seasotiya L, Yadav J, Mujeeb M. Efficacy of different extraction procedures on antibacterial activity of stem bark of *Butea monosperma* (Lam.) Kuntze. *Indian Journal of Natural Products and Resources* 2012; 3(4):551-556.
226. Sharma N, Garg V. Antihyperglycemic and antioxidative potential of hydroalcoholic extract of *Butea monosperma* Lam flowers in alloxan-induced diabetic mice. *Indian Journal of Experimental Biology* 2009;47(7):571-6.
227. Mathan G, Fatima G, Saxena A, Chandan B, Jaggi B, Gupta B, et al. Chemoprevention with aqueous extract of *Butea monosperma* flowers results in normalization of nuclear morphometry and inhibition of a proliferation marker in liver tumors. *Phytotherapy Research* 2011;25(3):324-8.
228. The Ayurvedic Pharmacopoeia of India, Part I Vol. V: Government of India, Ayush; 2001.
229. Sharma N, Shukla S. Hepatoprotective potential of aqueous extract of *Butea monosperma* against CCl₄ induced damage in rats. *Experimental and Toxicologic Pathology* 2011;63(7-8):671-6.
230. Sehrawat A, Khan T, Prasad L, Sultana S. *Butea monosperma* and chemomodulation: Protective role against thioacetamide-mediated hepatic alterations in Wistar rats. *Phytomedicine* 2006;13(3):157-63.
231. Moon DO, Kim MO, Choi YH, Hyun JW, Chang WY, Kim G-Y. Butein induces G2/M phase arrest and apoptosis in human hepatoma cancer cells through ROS generation. *Cancer Letters* 2010;288(2):204-13.
232. Rasheed Z, Akhtar N, Khan A, Khan KA, Haqqi TM. Butrin, isobutrin, and butein from medicinal plant *Butea monosperma* selectively inhibit nuclear factor- κ B in activated human mast cells: Suppression of tumor necrosis factor- α , interleukin (IL)-6, and IL-8. *Journal of Pharmacology and Experimental Therapeutics* 2010;333(2):354-63.
233. Chung C-H, Chang C-H, Chen S-S, Wang H-H, Yen J-Y, Hsiao C-J, et al. Butein inhibits angiogenesis of human endothelial progenitor cells via the translation dependent signaling pathway. *Evidence-Based Complementary and Alternative Medicine* 2013;2013:1-10.
234. Li Y, Ma C, Qian M, Wen Z, Jing H, Qian D. Butein induces cell apoptosis and inhibition of cyclooxygenase-2 expression in A549 lung cancer cells. *Molecular Medicine Reports* 2014;9(2):763-7.
235. Khan N, Adhami VM, Afaq F, Mukhtar H. Butein induces apoptosis and inhibits prostate tumor growth *in-vitro* and *in-vivo*. *Antioxidants & Redox Signaling* 2012;16(11):1195-204.
236. Choedon T, Shukla SK, Kumar V. Chemopreventive and anti-cancer properties of the aqueous extract of flowers of *Butea monosperma*. *Journal of Ethnopharmacology* 2010;129(2):208-13.

237. Sehrawat A, Sultana S. Chemoprevention by *Butea monosperma* of hepatic carcinogenesis and oxidative damage in male wistar rats. *Asian Pacific Journal of Cancer Prevention* 2006;7(1):140-148.
238. Choi JS, Jung SK, Jeon MH, Moon JN, Moon WS, Ji YH, et al. Effects of *Lycopersicon esculentum* extract on hair growth and alopecia prevention. *Journal of cosmetic science* 2013;64(6):429-43.
239. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. *New England Journal of Medicine* 1993;328(20):1450-6.
240. Heller FR, Descamps O, Hondekijn J-C. LDL oxidation: therapeutic perspectives. *Atherosclerosis* 1998;137:S25-S31.
241. Morris DL, Kritchevsky SB, Davis C. Serum carotenoids and coronary heart disease: the lipid research clinics coronary primary prevention trial and follow-up study. *Jama* 1994;272(18):1439-41.
242. Bernal C, Martín-Pozuelo G, Lozano AB, Sevilla Á, García-Alonso J, Canovas M, et al. Lipid biomarkers and metabolic effects of lycopene from tomato juice on liver of rats with induced hepatic steatosis. *The Journal of Nutritional Biochemistry* 2013;24(11):1870-81.
243. Thukhammee W, Wattanathorn J, Muchimapura S, Uriyapongson J, Tong-Un T, Wannanon P. The cognitive enhancing effect of tomato pomace. *American Journal of Applied Sciences* 2012;9(11):1776-81.
244. Franceschi S, Bidoli E, Vecchia CL, Talamini R, D'Avanzo B, Negri E. Tomatoes and risk of digestive-tract cancers. *International Journal of Cancer* 1994;59(2):181-4.
245. Levy J, Bosin E, Feldman B, Giat Y, Miinster A, Danilenko M, et al. Lycopene is a more potent inhibitor of human cancer cell proliferation than either α -carotene or β -carotene. *Nutrition and Cancer* 1995; 24(3):257-66.
246. Sohel F, Yeasmin MS. Antimicrobial screening of *Cassia fistula* and *Mesua ferrea*. *Journal Of Medical Sciences* 2004;4(1):24-9.
247. Thirumal M, Srimanthula S, Kishore G. *Cassia fistula* Linn-Pharmacognostical, phytochemical and pharmacological review. *Critical Review in Pharmaceutical Sciences* 2012;1(1):43-65.
248. Danish M, Singh P, Mishra G, Srivastava S, Jha K, Khosa R. *Cassia fistula* Linn.(Amulthus)-An important medicinal plant: A review of its traditional uses, phytochemistry and pharmacological properties. *Journal of Natural Product and Plant Resources* 2011;1(1):101-18.
249. Irshad M, Man S, Rizvi M. Assessment of anthelmintic activity of *Cassia fistula* L. *Middle East Journal of Scientific Research* 2010;5(5):346-9.
250. Duraipandiyam V, Ignacimuthu S. Antibacterial and antifungal activity of *Cassia fistula* L.: An ethnomedicinal plant. *Journal of Ethnopharmacology* 2007;112(3):590-4.

251. Yadav R, Jain G. Antifertility effect of aqueous extract of seeds of *Cassia fistula* in female rats. *Advances in Contraception* 1999;15(4):293-301.
252. Ilavarasan R, Malika M, Venkataraman S. Anti-inflammatory and antioxidant activities of *Cassia fistula* Linn bark extracts. *African Journal of Traditional, Complementary and Alternative medicines* 2006;2(1):70-85.
253. Siddhuraju P, Mohan P, Becker K. Studies on the antioxidant activity of Indian Laburnum (*Cassia fistula* L.): a preliminary assessment of crude extracts from stem bark, leaves, flowers and fruit pulp. *Food Chemistry* 2002;79(1):61-7.
254. Manonmani G, Bhavapriya V, Kalpana S, Govindasamy S, Apparathanam T. Antioxidant activity of *Cassia fistula* (Linn.) flowers in alloxan induced diabetic rats. *Journal of Ethnopharmacology* 2005;97(1):39-42.
255. Mazumder U, Gupta M, Rath N. CNS activities of *Cassia fistula* in mice. *Phytotherapy Research* 1998;12(7):520-2.
256. Jehangir A, Nagi A, Shahzad M, Zia A. The hepatoprotective effect of *Cassia fistula* (amaltas) leaves in isoniazid and rifampicin induced hepatotoxicity in rodents. *Biomedica* 2010;26(1):25-9.
257. Gupta UC, Jain G. Study on hypolipidemic activity of *Cassia fistula* legume in rats. *Asian Journal of Experimental Sciences* 2009;23(1):241-8.
258. Lin M-L, Chung J-G, Lu Y-C, Yang C-Y, Chen S-S. Rhein inhibits invasion and migration of human nasopharyngeal carcinoma cells *in-vitro* by down-regulation of matrix metalloproteinases-9 and vascular endothelial growth factor. *Oral oncology* 2009;45(6):531-7.
259. Liu J, Zhang K, Zhen Y-Z, Wei J, Hu G, Gao J-L, et al. Antitumor activity of rhein lysinate against human glioma U87 cells *in-vitro* and *in-vivo*. *Oncology Reports* 2016;35(3):1711-7.
260. Wang SE, Lin CL, Hsu CH, Sheu SJ, Chien CT, Wu CH. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease. *Drug design, Development and Therapy* 2015;9:887-900.
261. Martin G, Melito G, Rivera E, Levin E, Davio C, Cricco G, et al. Effect of tamoxifen on intraperitoneal N-nitroso-N-methylurea induced tumors. *Cancer Letters* 1996;100(1):227-34.
262. Karia PD, Patel KV, Rathod SS. Breast cancer amelioration by *Butea monosperma in-vitro* and *in-vivo*. *Journal of Ethnopharmacology* 2018;217:54-62.
263. Kubatka P, Ahlers I, Ahlersová E, Adámeková E, Luk P, Bojková B, et al. Chemoprevention of mammary carcinogenesis in female rats by rofecoxib. *Cancer Letters* 2003;202(2):131-6.
264. Puertollano M, Carrera M, Puertollano E, Alvarez de Cienfuegos G, Ramirez-Expósito M, De Pablo M, et al. Analysis of caspase activities in rat mammary tumours induced by N-methyl-nitrosourea. *Oncology Reports* 2008;20(3):657-62.

265. Thorpe MP, Valentine RJ, Moulton CJ, Johnson AJ, Evans EM, Layman DK. Breast tumors induced by N-methyl-N-nitrosourea are damaging to bone strength, structure, and mineralization in the absence of metastasis in rats. *Journal of Bone and Mineral Research* 2011;26(4):769-76.
266. Allred CD, Allred KF, Ju YH, Clausen LM, Doerge DR, Schantz SL, et al. Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague–Dawley rats. *Carcinogenesis* 2004;25(2):211-8.
267. Evers N, van de Klundert T, van Aesch Y, Wang S, de Roos W, Romano A, et al. Human T47D-ER β breast cancer cells with tetracycline-dependent ER β expression reflect ER α /ER β ratios in rat and human breast tissue. *Toxicology In Vitro* 2013;27(6):1753-61.
268. Rengarajan T, Nandakumar N, Balasubramanian MP. D-pinitol prevents rat breast carcinogenesis induced by 7, 12-Dimethylbenz [a] anthracene through inhibition of Bcl-2 and induction of p53, caspase-3 proteins and modulation of hepatic biotransformation enzymes and antioxidants. *Biomedicine & Preventive Nutrition* 2013;3(1):31-41.
269. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *Journal of Biological Chemistry* 1951;193:265-75.
270. Slater T, Sawyer B. The stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reactions in rat liver fractions *in-vitro*. General features of the systems used. *The Biochemical Journal* 1971;123(5):805-14.
271. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. *Biochimica et Biophysica Acta-General Subjects* 1979;582(1):67-78.
272. Misra HP, Fridovich I. The oxidation of phenylhydrazine: superoxide and mechanism. *Biochemistry* 1976;15(3):681-7.
273. Aebi H, Wyss SR, Scherz B, Skvaril F. Heterogeneity of erythrocyte catalase II: isolation and characterization of normal and variant erythrocyte catalase and their subunits. *European Journal of Biochemistry* 1974;48(1):137-45.
274. West DC, Thompson WD, Sells PG, Burbridge MF. Angiogenesis assays using chick chorioallantoic membrane. *Angiogenesis protocols: Springer*; 2001;46:107-29.
275. Chen Z, Wen Z, Bai X. *In-vivo* chick chorioallantoic membrane (CAM) angiogenesis assay. *Bio-protocol* 2013;3(18):1-5.
276. Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, et al. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. *Journal of Surgical Research* 1991;50(3):245-51.
277. Sampaio MU, Correia MTS, Oliva MLV. *Bauhinia forficata* lectin (BfL) induces cell death and inhibits integrin-mediated adhesion on MCF7 human breast cancer cells. *Biochimica et Biophysica Acta* 1840;2014:2262-71.

278. Tang EL, Rajarajeswaran J, Fung SY, Kanthimathi M. Antioxidant activity of *Coriandrum sativum* and protection against DNA damage and cancer cell migration. *BMC Complementary And Alternative Medicine* 2013;13(1)1-13.
279. Sainadh N, Nagarathna PK, Kulkarni SC. Evaluation of anti-cancer activity of *Kigelia africana* on EAC induced solid tumors. *Research and Review: Journal of Pharmacology and Toxicological Studies* 2013;1:20-5.
280. Ozaslan M, Karagoz ID, Kilic IH, Guldur ME. Ehrlich ascites carcinoma. *African Journal of Biotechnology* 2011;10(13):2375-8.
281. Xanthopoulos J, Romano A, Majumdar SK. Response of mouse breast cancer cells to anastrozole, tamoxifen, and the combination. *BioMed Research International* 2005;2005(1):10-9.
282. Wu WM, Lin BF, Su YC, Suen JL, Chiang BL. Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice. *Scandinavian Journal of Immunology* 2000;52(4):393-400.
283. Sainadh N, Pkm N, C VK KS. Evaluation of Anti-Cancer Activity of *Kigelia africana* on EAC Induced Breast Tumors. *Journal of Pharmacy and Pharmaceutical Sciences* 2013;2(3):78-84.
284. Sharma B, Dhamija I, Kumar S, Chaudhary H. *In-vitro* and *in-vivo* evaluation of antitumor activity of methanolic extract of *Argyrea nervosa* leaves on Ehrlich ascites carcinoma. *Bangladesh Journal of Pharmacology* 2015;10(2):399-408.
285. Hussein MA, Boshra SA. Antitumor and structure antioxidant activity relationship of colchicine on Ehrlich ascites carcinoma (EAC) in female mice. *International Journal of Drug Delivery* 2013;5(4):430-437.
286. Shen J, Andersen R, Albert PS, Wenger N, Glaspy J, Cole M, et al. Use of complementary/alternative therapies by women with advanced-stage breast cancer. *BMC Complementary and Alternative Medicine* 2002;2(1):8-15.
287. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. *Journal of Clinical Oncology* 2000;18(13):2505-14.
288. Navo MA, Phan J, Vaughan C, Palmer JL, Michaud L, Jones KL, et al. An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. *Journal of Clinical Oncology* 2004;22(4):671-7.
289. Swarup AB, Barrett W, Jazieh AR. The use of complementary and alternative medicine by cancer patients undergoing radiation therapy. *American Journal of Clinical Oncology* 2006;29(5):468-73.
290. Cai Y, Luo Q, Sun M, Corke H. Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer. *Life Sciences* 2004;74(17):2157-84.

291. Hajare MA, Choudhary M, Gupta NS. Plant review: Phytochemical constituents and their important characterization of *Butea monosperma* (palash). International Journal of Application or Innovation in Engineering & Management 2013;5:1-4.
292. Padghan S. Phytochemical and physicochemical screening of different extracts of *Butea monosperma* flowers. International Research Journal of Science and Engineering 2018;A3:161-4.
293. Roh MK, Jeon MJ, Moon JN, Moon WS, Park SM, Choi JS. A simple method for the isolation of lycopene from *Lycopersicon esculentum*. Botanical Sciences 2013;91(2):187-92.
294. Palozza P, Colangelo M, Simone R, Catalano A, Boninsegna A, Lanza P, et al. Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines. Carcinogenesis 2010;31(10):1813-21.
295. Chen ML, Lin YH, Yang CM, Hu ML. Lycopene inhibits angiogenesis both *in-vitro* and *in-vivo* by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways. Molecular Nutrition & Food Research 2012;56(6):889-99.
296. Palozza P, Sheriff A, Serini S, Boninsegna A, Maggiano N, Ranelletti FO, et al. Lycopene induces apoptosis in immortalized fibroblasts exposed to tobacco smoke condensate through arresting cell cycle and down-regulating cyclin D1, pAKT and pBad. Apoptosis 2005;10(6):1445-56.
297. Huang C-S, Liao J-W, Hu M-L. Lycopene inhibits experimental metastasis of human hepatoma SK-Hep-1 cells in athymic nude mice. The Journal of Nutrition 2008;138(3):538-43.
298. Prakash P, Russell RM, Krinsky NI. *In-vitro* inhibition of proliferation of estrogen-dependent and estrogen-independent human breast cancer cells treated with carotenoids or retinoids. The Journal of Nutrition 2001;131(5):1574-80.
299. Sakulpanich A, Gritsanapan W. Extraction method for high content of anthraquinones from *Cassia fistula* pods. Journal of Health Research 2008;22(4):167-72.
300. Luximon-Ramma A, Bahorun T, Soobrattee MA, Aruoma OI. Antioxidant activities of phenolic, proanthocyanidin, and flavonoid components in extracts of *Cassia fistula*. Journal of Agricultural and Food Chemistry 2002;50(18):5042-7.
301. Kulkarni A, Govindappa M, Ramachandra Y, Koka P. GC-MS analysis of methanol extract of *Cassia fistula* and its *in-vitro* anticancer activity on human prostate cancer cell line. Indo American Journal of Pharmaceutical Research 2015;5(2):937-44.
302. Aviello G, Rowland I, Gill CI, Acquaviva AM, Capasso F, McCann M, et al. Anti-proliferative effect of rhein, an anthraquinone isolated from Cassia species, on Caco-2 human adenocarcinoma cells. Journal of Cellular and Molecular Medicine 2010;14(7):2006-14.

303. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100(1):57-70.
304. Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. *Breast Cancer Research* 2011;13(4):215-21.
305. Brooks SC, Locke ER, Soule HD. Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. *Journal of Biological Chemistry* 1973;248(17):6251-3.
306. Subik K, Lee J-F, Baxter L, Strzepek T, Costello D, Crowley P, et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. *Breast Cancer: Basic and Clinical Research* 2010;4:35-41.
307. Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. *Breast Disease* 2010;32(1-2):35-48.
308. van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. *Cancer Cell Culture: Methods and Protocols* 2011:237-45.
309. Dorgan JF, Sowell A, Swanson CA, Potischman N, Miller R, Schussler N, et al. Relationships of serum carotenoids, retinol, α -tocopherol, and selenium with breast cancer risk: results from a prospective study in Columbia, Missouri (United States). *Cancer Causes & Control* 1998;9(1):89-97.
310. Dhanapal R, Saraswathi T, Govind RN. Cancer cachexia. *Journal of Oral and Maxillofacial Pathology* 2011;15(3):257-60.
311. Ramos EJ, Suzuki S, Marks D, Inui A, Asakawa A, Meguid MM. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. *Current Opinion in Clinical Nutrition & Metabolic Care* 2004;7(4):427-34.
312. Sosa V, Moliné T, Somoza R, Paciucci R, Kondoh H, LLeonart ME. Oxidative stress and cancer: An overview. *Ageing Research Reviews* 2013;12(1):376-90.
313. Kolanjiappan K, Manoharan S, Kayalvizhi M. Measurement of erythrocyte lipids, lipid peroxidation, antioxidants and osmotic fragility in cervical cancer patients. *Clinica Chimica Acta* 2002;326(1):143-9.
314. Veskokoukis AS, Tsatsakis AM, Kouretas D. Dietary oxidative stress and antioxidant defense with an emphasis on plant extract administration. *Cell Stress and Chaperones* 2012;17(1):11-21.
315. Li D, Zhang W, Sahin AA, Hittelman WN. DNA adducts in normal tissue adjacent to breast cancer: a review. *Cancer Detection and Prevention* 1998;23(6):454-62.
316. Palani V, Senthilkumaran R, Govindasamy S. Biochemical evaluation of antitumor effect of Muthu Marunthu (a herbal formulation) on experimental fibrosarcoma in rats. *Journal of Ethnopharmacology* 1999;65(3):257-65.

317. Khanzode SS, Muddeshwar M, Khanzode SD, Dakhale GN. Antioxidant enzymes and lipid peroxidation in different stages of breast cancer. *Free Radical Research* 2004;38(1):81-5.
318. Sharma N, Garg V. Antihyperglycemic and antioxidative potential of hydroalcoholic extract of *Butea monosperma* Lam flowers in alloxan-induced diabetic mice. *Indian Journal of Experimental Biology* 2009; 47(7):571-6.
319. Krinsky NI. Carotenoids as antioxidants. *Nutrition* 2001;17(10):815-7.
320. Paiva SA, Russell RM. β -Carotene and other carotenoids as antioxidants. *Journal of the American College of Nutrition* 1999;18(5):426-33.
321. Fiedor J, Burda K. Potential role of carotenoids as antioxidants in human health and disease. *Nutrients* 2014;6(2):466-88.
322. Miller NJ, Sampson J, Candeias LP, Bramley PM, Rice-Evans CA. Antioxidant activities of carotenes and xanthophylls. *FEBS letters* 1996;384(3):240-2.
323. Rao A, Agarwal S. Bioavailability and *in-vivo* antioxidant properties of lycopene from tomato products and their possible role in the prevention of cancer. *Nutrition and Cancer* 1998;31(3):199-203.
324. Pool-Zobel B, Bub A, Müller H, Wollowski I, Rechkemmer G. Consumption of vegetables reduces genetic damage in humans: first results of a human intervention trial with carotenoid-rich foods. *Carcinogenesis* 1997;18(9):1847-50.
325. Laronga C. Patient education: breast cancer guide to diagnosis and treatment (beyond the basics). Available from: <https://www.uptodate.com/contents/breast-cancer-guide-to-diagnosis-and-treatment-beyond-the-basics>.
326. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). *Archives of pathology & laboratory medicine* 2010;134(7):e48-e72.
327. Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. *Journal of Clinical Oncology* 2011;29(15):e458.
328. Thordarson G, Lee AV, McCarty M, Van Horn K, Chu O, Chou Y-C, et al. Growth and characterization of N-methyl-N-nitrosourea-induced mammary tumors in intact and ovariectomized rats. *Carcinogenesis* 2001;22(12):2039-47.
329. Singhal H, Greene ME, Tarulli G, Zarnke AL, Bourgo RJ, Laine M, et al. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. *Science Advances* 2016;2(6).
330. Lange CA, Yee D. Progesterone and breast cancer. *Women's Health* 2008;4(2):151-62.

331. Shah K, Baxi A. Phytochemical studies and antioestrogenic activity of *Butea frondosa* flowers. *Indian Journal of Pharmaceutical Sciences* 1990;52(6):272-5.
332. Osawa Y, Tochigi B, Tochigi M, Ohnishi S, Watanabe Y, Bullion K, et al. Aromatase inhibitors in cigarette smoke, tobacco leaves and other plants. *Journal of Enzyme Inhibition* 1990;4(2):187-200.
333. Apel W, Bock R. Enhancement of carotenoid biosynthesis in transplastomic tomatoes by induced lycopene-to-provitamin A conversion. *Plant Physiology* 2009;151(1):59-66.
334. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. *Vascular health and risk management* 2006;2(3):213-9.
335. Reuben SC, Gopalan A, Petit DM, Bishayee A. Modulation of angiogenesis by dietary phytoconstituents in the prevention and intervention of breast cancer. *Molecular Nutrition & Food Research* 2012;56(1):14-29.
336. West DC, Thompson WD, Sells PG, Burbridge MF. Angiogenesis assays using chick chorioallantoic membrane. *Angiogenesis Protocols* 2001;46:107-29.
337. Deryugina EI, Quigley JP. Chick embryo chorioallantoic membrane models to quantify angiogenesis induced by inflammatory and tumor cells or purified effector molecules. *Methods in Enzymology* 2008;444:21-41.
338. Folkman J, editor *Angiogenesis and apoptosis*. *Seminars in Cancer Biology* 2003;13(2): 159-67.
339. Elmore S. Apoptosis: a review of programmed cell death. *Toxicologic Pathology* 2007;35(4):495-516.
340. Pistrutto G, Trisciuglio D, Ceci C, Garufi A, D'Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. *Aging* 2016;8(4):603-19.
341. Wong RS. Apoptosis in cancer: from pathogenesis to treatment. *Journal of Experimental & Clinical Cancer Research* 2011;30(1):87-100.
342. Vermes I, Haanen C, Steffens-Nakken H, Reutellingsperger C. A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. *Journal of Immunological Methods* 1995;184(1):39-51.
343. Palozza P, Serini S, Di Nicuolo F, Calviello G. Modulation of apoptotic signalling by carotenoids in cancer cells. *Archives of Biochemistry and Biophysics* 2004;430(1):104-9.
344. Palozza P, Serini S, Maggiano N, Angelini M, Boninsegna A, Di Nicuolo F, et al. Induction of cell cycle arrest and apoptosis in human colon adenocarcinoma cell lines by β -carotene through down-regulation of cyclin A and Bcl-2 family proteins. *Carcinogenesis* 2002;23(1):11-8.

345. Irshad M, Mehdi SJ, Al-Fatlawi AA, Zafaryab M, Ali A, Ahmad I, et al. Phytochemical composition of *Cassia fistula* fruit extracts and its anticancer activity against human cancer cell lines. *Journal of Biologically Active Products from Nature* 2014;4(3):158-70.
346. Hulkower KI, Herber RL. Cell migration and invasion assays as tools for drug discovery. *Pharmaceutics* 2011;3(1):107-24.
347. Ahmed OM, Ahmed RR. Anti-proliferative and apoptotic efficacy of diallyl disulfide on Ehrlich ascites carcinoma. *Hepatoma Research* 2015;1(2):67-74.
348. Sreelatha S, Padma P, Umasankari E. Evaluation of anticancer activity of ethanol extract of *Sesbania grandiflora* (Agati Sesban) against Ehrlich ascites carcinoma in Swiss albino mice. *Journal of Ethnopharmacology* 2011;134(3):984-7.
349. Devmurari V, Jivani N. Anticancer evaluation of *Artemisia nilagirica*. *International Journal of PharmTech Research* 2010;2:1603-8.
350. Sreelatha S, Dinesh E, Uma C. Antioxidant properties of Rajgira (*Amaranthus paniculatus*) leaves and potential synergy in chemoprevention. *Asian Pacific Journal of Cancer Prevention* 2012;13(6):2775-80.
351. George BP, Parimelazhagan T, Sajeesh T, Saravanan S. Antitumor and wound healing properties of *Rubus niveus* Thunb. root. *Journal of Environmental Pathology, Toxicology and Oncology* 2014;33(2):145-58.
352. Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. *Breast Cancer Research and Treatment* 1995;36(2):193-204.
353. Dey A, Lane DP, Verma CS. Modulating the p53 pathway. *Seminars in Cancer Biology* 2010;20(1):3-9.
354. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. *Cancer Science* 1994;85(10):1045-9.
355. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo T-K, et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. *Clinical Cancer Research* 1999;5(5):1041-56.
356. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. *Nature Reviews. Cancer* 2003;3(6):401-410.
357. Folkman J. Tumor angiogenesis: therapeutic implications. *New England Journal of Medicine* 1971;285(21):1182-6.
358. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. *The oncologist* 2004;9(Suppl 1):2-10.
359. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. *Nature* 1992;359(6398):843-5.

360. Harmey JH, Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: Implications for anti-angiogenic therapy. *Bioessays* 2002;24(3):280-3.
361. Campbell N, Kellenberger L, Greenaway J, Moorehead R, Linnerth-Petrik N, Petrik J. Extracellular matrix proteins and tumor angiogenesis. *Journal of Oncology* 2010;2010:1-13.
362. Rabbani SA. Metalloproteases and urokinase in angiogenesis and tumor progression. *In vivo* 1998;12(1):135-42.
363. Lai Y-W, Wang S-W, Chang C-H, Liu S-C, Chen Y-J, Chi C-W, et al. Butein inhibits metastatic behavior in mouse melanoma cells through VEGF expression and translation-dependent signaling pathway regulation. *BMC Complementary and Alternative Medicine* 2015;15(1):445-455.
364. Zhou Y-X, Xia W, Yue W, Peng C, Rahman K, Zhang H. Rhein: a review of pharmacological activities. *Evidence-Based Complementary and Alternative Medicine* 2015;2015:1-10.
365. Wu GS, Ding Z. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. *Oncogene* 2002;21(1):1-8.
366. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, et al. p53-dependent apoptosis suppresses tumor growth and progression *in-vivo*. *Cell* 1994;78(4):703-11.
367. Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM. p53 as a target for the treatment of cancer. *Cancer Treatment Reviews* 2014;40(10):1153-60.
368. Soengas MS, Alarcon R, Yoshida H, Hakem R, Mak T, Lowe S. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. *Science* 1999;284(5411):156-9.
369. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis-the p53 network. *Journal of Cell Science* 2003;116(20):4077-85.
370. Schuler M, Bossy-Wetzl E, Goldstein JC, Fitzgerald P, Green DR. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. *Journal of Biological Chemistry* 2000;275(10):7337-42.
371. Schuler M, Green D. Mechanisms of p53-dependent apoptosis. *Biochemical Society Transactions* 2001;29(Pt 6):684-8.
372. Chang C-Y, Chan H-L, Lin H-Y, Way T-D, Kao M-C, Song M-Z, et al. Rhein induces apoptosis in human breast cancer cells. *Evidence-Based Complementary and Alternative Medicine* 2012;2012:1-8.
373. Weigelt B, Peterse JL, Van't Veer LJ. Breast cancer metastasis: markers and models. *Nature Reviews. Cancer* 2005;5(8):591-602.

374. Martin TA, Ye L, Sanders AJ, Lane J, Jiang WG. Cancer invasion and metastasis: molecular and cellular perspective. *Madame Curie Bioscience Database* 2013: 1-37.
375. Cao R, Wang L-p. Serological diagnosis of liver metastasis in patients with breast cancer. *Cancer Biology & Medicine* 2012;9(1):57-62.
376. Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. *Cell Cycle* 2009;8(20):3267-73.
377. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. *Nature Reviews. Cancer* 2006;6(2):130-40.
378. Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. *Molecular and Cellular Endocrinology* 2014;382(1):673-82.
379. Zhou X-L, Fan W, Yang G, Yu M-X. The clinical significance of PR, ER, NF- κ B, and TNF- α in breast cancer. *Disease Markers* 2014;2014:1-7.
380. Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. *The Journal of Clinical Investigation* 2007;117(12):3660-3663.
381. Shalamzari SA, Agha-Alinejad H, Alizadeh S, Shahbazi S, Khatib ZK, Kazemi A, et al. The effect of exercise training on the level of tissue IL-6 and vascular endothelial growth factor in breast cancer bearing mice. *Iranian Journal of Basic Medical Sciences* 2014;17(4):231-258.
382. Duffy M. The role of proteolytic enzymes in cancer invasion and metastasis. *Clinical & Experimental Metastasis* 1992;10(3):145-55.
383. Tappel A. Lysosomal enzymes and initiation of breast cancer. *Medical Hypotheses* 2005;64(2):288-9.
384. de Reuck AS, Cameron MP. Lysosomes: Distribution in Animals, Hydrolytic Capacity and Other Properties. In: Tappel A, Sawant P, Shibko S, editors. *Ciba Foundation Symposium-Anterior Pituitary Secretion*, 1st Ed. Wiley Online Library; 1963. p. 78-110.
385. Tryggvason K, Höyhty M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. *Biochimica et Biophysica Acta-Reviews on Cancer* 1987;907(3):191-217.
386. Boyer MJ, Tannock IF. Lysosomes, lysosomal enzymes, and cancer. *Advances in Cancer Research* 1992;60:269-91.
387. Potter VR. Biochemical perspectives in cancer research. *Cancer Research* 1964;24(7):1085-98.
388. Thangaraju M, Rameshbabu J, Vasavi H, Ilanchezhian S, Vinitha R, Sachdanandam P. The salubrious effect of tamoxifen on serum marker enzymes, glycoproteins, and lysosomal enzymes level in breast cancer women. *Molecular and Cellular Biochemistry* 1998;185(1-2):85-94.

389. Calvo P, Barba J, Cabezas J. Serum β -N-acetylglucosaminidase, β -d-glucosidase, α -d-glucosidase, β -d-fucosidase, α -l-fucosidase and β -d-galactosidase levels in acute viral hepatitis, pancreatitis, myocardial infarction and breast cancer. *Clinica Chimica Acta* 1982;119(1):15-9.
390. Zhang L, Chen W, Li X. A novel anticancer effect of butein: Inhibition of invasion through the ERK1/2 and NF- κ B signaling pathways in bladder cancer cells. *FEBS letters* 2008;582(13):1821-8.
391. Chua AWL, Hay HS, Rajendran P, Shanmugam MK, Li F, Bist P, et al. Butein downregulates chemokine receptor CXCR4 expression and function through suppression of NF- κ B activation in breast and pancreatic tumor cells. *Biochemical Pharmacology* 2010;80(10):1553-62.
392. Lau GTY, Huang H, Lin S-m, Leung LK. Butein downregulates phorbol 12-myristate 13-acetate-induced COX-2 transcriptional activity in cancerous and non-cancerous breast cells. *European Journal of Pharmacology* 2010;648:24-30.
393. Hwang ES, Lee HJ. Inhibitory effects of lycopene on the adhesion, invasion, and migration of SK-Hep1 human hepatoma cells. *Experimental Biology and Medicine* 2006;231(3):322-7.
394. Akinbami A, Popoola A, Adediran A, Dosunmu A, Oshinaike O, Adebola P, et al. Full blood count pattern of pre-chemotherapy breast cancer patients in Lagos, Nigeria. *Caspian Journal of Internal Medicine* 2013;4(1):574-9.